DaYan BioMedical International Co., Ltd. Q4 2025 Financial Report
Key facts
- DaYan BioMedical International Co., Ltd. Q4 2025 Financial Report
- DaYan BioMedical International Co., Ltd. reported Q4 2025 basic EPS of 0.51, operating revenue of 1.895 billion, and net income after tax of 338 million.
- Source: PR Times
- Date: December 1, 2025
Direct answer
DaYan BioMedical International Co., Ltd. reported Q4 2025 basic EPS of 0.51, operating revenue of 1.895 billion, and net income after tax of 338 million.
- Citation
- DaYan BioMedical International Co., Ltd. Q4 2025 Financial Report (December 1, 2025), PR Times
- Source
- PR Times
- Date
- December 1, 2025
DaYan BioMedical International Co., Ltd. reported Q4 2025 basic EPS of 0.51, operating revenue of 1.895 billion, and net income after tax of 338 million.
📋 Article Processing Timeline
- 📰 Published: December 1, 2025 at 09:00
- 🔍 Collected: April 7, 2026 at 08:00 (3047h 0m after Published)
- 🤖 AI Analyzed: April 8, 2026 at 00:21 (16h 21m after Collected)
Company Code: 7780 Company Name: DaYan BioMedical International Co., Ltd. Industry: Food Industry Year/Quarter: 2025 Q4 Basic Earnings Per Share: 0.51 NTD Operating Revenue: 1.895 billion NTD Net Income After Tax: 338 million NTD
FAQ
What are the key facts in this article?
DaYan BioMedical International Co., Ltd. reported Q4 2025 basic EPS of 0.51, operating revenue of 1.895 billion, and net income after tax of 338 million.
What is the direct answer?
DaYan BioMedical International Co., Ltd. reported Q4 2025 basic EPS of 0.51, operating revenue of 1.895 billion, and net income after tax of 338 million.
What is the source and date?
PR Times: https://openapi.twse.com.tw/financial/twse-fin-7780-2025Q4 | December 1, 2025